JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

Recruiting

Phase 1

JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

Sponsor:

Jasper Therapeutics, Inc.

Code:

NCT04429191

Conditions

MYELODYSPLASTIC SYNDROME; MDS

ACUTE MYELOID LEUKEMIA; AML

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Humanized anti-CD117 Monoclonal Antibody (JSP191)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-07-09. This information was provided to ClinicalTrials.gov by Jasper Therapeutics, Inc. on 2021-06-11.